Risk of Arrhythmic Death in Patients With Nonischemic Cardiomyopathy: JACC Review Topic of the Week.

cardiac magnetic resonance imaging computational modeling nonischemic cardiomyopathy sudden cardiac death ventricular arrhythmias

Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
22 08 2023
Historique:
received: 05 12 2022
revised: 21 04 2023
accepted: 30 05 2023
medline: 18 8 2023
pubmed: 17 8 2023
entrez: 17 8 2023
Statut: ppublish

Résumé

Nonischemic cardiomyopathy (NICM) is common and patients are at significant risk for early mortality secondary to ventricular arrhythmias. Current guidelines recommend implantable cardioverter-defibrillator (ICD) therapy to decrease sudden cardiac death (SCD) in patients with heart failure and reduced left ventricular ejection fraction. However, in randomized clinical trials comprised solely of patients with NICM, primary prevention ICDs did not confer significant mortality benefit. Moreover, left ventricular ejection fraction has limited sensitivity and specificity for predicting SCD. Therefore, precise risk stratification algorithms are needed to define those at the highest risk of SCD. This review examines mechanisms of sudden arrhythmic death in patients with NICM, discusses the role of ICD therapy and treatment of heart failure for prevention of SCD in patients with NICM, examines the role of cardiac magnetic resonance imaging and computational modeling for SCD risk stratification, and proposes new strategies to guide future clinical trials on SCD risk assessment in patients with NICM.

Identifiants

pubmed: 37587585
pii: S0735-1097(23)06019-9
doi: 10.1016/j.jacc.2023.05.064
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

735-747

Informations de copyright

Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures Dr Chrispin has received consulting fees from Biosense Webster; and has received honorarium from Abbott. Dr Navara has equity ownership in SafeBeat Rx. Dr Torbe has ownership of Boston Scientific stocks. Dr Cheung has received consulting fees from Abbott, Biotronik, and Boston Scientific; has received research grant support from Boston Scientific; and has received fellowship grant support from Abbott, Biosense, Biotronik, Boston Scientific, and Medtronic. Dr Lakdawala has received research support from Pfizer Inc; and has received consulting fees from Pfizer Inc, Bristol Myers Squibb, Cytokinetics, and Tenaya Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Jonathan Chrispin (J)

Department of Medicine, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Electronic address: chrispin@jhmi.edu.

Faisal M Merchant (FM)

Department of Medicine, Emory University, Atlanta, Georgia, USA.

Neal K Lakdawala (NK)

Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Katherine C Wu (KC)

Department of Medicine, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Gordon F Tomaselli (GF)

Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.

Rachita Navara (R)

Division of Cardiac Electrophysiology, University of California, San Fransisco, California, USA.

Estelle Torbey (E)

Division of Electrophysiology, Brown University, Providence, Rhode Island, USA.

Amrut V Ambardekar (AV)

Department of Medicine, Division of Cardiology, University of Colorado, Aurora, Colorado, USA.

Rajesh Kabra (R)

Kansas City Heart Rhythm Institute, Overland Park, Kansas, USA.

Eloisa Arbustini (E)

Center for Inherited Cardiovascular Diseases, IRCCS Foundation Policlinico San Matteo, Pavia, Italy.

Jagat Narula (J)

McGovern Medical School at the University of Texas Health Science Center, Houston, Texas, USA.

Maya Guglin (M)

Advanced Heart Failure and Transplant, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Christine M Albert (CM)

Cardiac Electrohysiology, Cedars Sinai Smidt Heart Institute, Los Angeles, California, USA.

Sumeet S Chugh (SS)

Cardiac Electrohysiology, Cedars Sinai Smidt Heart Institute, Los Angeles, California, USA.

Natalia Trayanova (N)

Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, USA.

Jim W Cheung (JW)

Division of Cardiology, Weill Cornell Medicine, New York, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH